STRIVERDI RESPIMAT

Olodaterol

STRIVERDI RESPIMAT

LABA SMI

Olodaterol · Boehringer Ingelheim

Clinical Reference

Active Medication & Mechanism

Olodaterol hydrochloride LABA
2.5 mcg per actuation

Long-acting beta2-adrenergic agonist. Selectively stimulates beta2-receptors on airway smooth muscle, increasing intracellular cAMP and producing sustained bronchodilation (~24 hours).

FDA-Approved Dosing by Indication

// approval varies by strength + age

COPD

1/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
2.5 mcg	Adults (≥18 years)	2 puffs (5 mcg total) once daily at the same time each day Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.	5 mcg	FDA Approved

2.5 mcg FDA Approved

Pop · Adults (≥18 years)

2 puffs (5 mcg total) once daily at the same time each day

Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.

Total · 5 mcg

Asthma

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	All patients	—	—	Not Approved Striverdi is NOT indicated for asthma. LABA without ICS increases risk of serious asthma events.

Any strength Not Approved

Pop · All patients

—

Total · — Striverdi is NOT indicated for asthma. LABA without ICS increases risk of serious asthma events.

Acute Use

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	Acute bronchospasm / rescue	—	—	Not Approved Not for acute bronchospasm. Use a SABA.

Any strength Not Approved

Pop · Acute bronchospasm / rescue

—

Total · — Not for acute bronchospasm. Use a SABA.